The median OS improvement is anticipated to surpass one year ... "J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial" was originally created and published by Clinical ...
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ... The median OS improvement is anticipated to surpass one year. The MARIPOSA trial, ...
Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.
SURPASS-ET Clinical Results Clinical Trial Overview SURPASS-ET (NCT04285086) is a global Phase 3, randomized, open-label, active-controlled clinical trial evaluating the efficacy, safety and ...
Alphabet Inc. consistently surpasses the Rule of 40, with a current score of 42.8, showcasing an excellent balance of growth ...
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), retaining the price target ...
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback